Answers are grounded in this paper and cite their sources.
Probiotics, defined as live non-pathogenic microorganisms that confer health benefits to the host when administered in adequate amounts, have gained substantial scientific and commercial interest. The term, derived from Latin and Greek roots meaning "for life," was introduced in 1953 by Werner Kollath, but the concept dates back to ancient civilizations that consumed fermented milk products. Unlike previous reviews that focus on single applications, this comprehensive review systematically examines the historical background, regulatory definitions, strain selection criteria, and multifaceted mechanisms of action of probiotics, including enhancement of the epithelial barrier, competitive exclusion of pathogens, production of antimicrobial substances, and immune modulation. Furthermore, we present a comprehensive update on evidence-based therapeutic applications, focusing on gastrointestinal disorders (antibiotic-associated diarrhea, irritable bowel syndrome), metabolic diseases (diabetes, obesity), mental health (depression), urinary and vaginal infections, oral health, and dermatological conditions (including wound healing). Special attention is given to recent clinical data (2020–2026) and emerging applications. Safety considerations and future directions, including personalized probiotics and strain-specific optimization, are also discussed. This review aims to provide a clear, structured overview for researchers and clinicians, while identifying knowledge gaps that require further investigation.
No takes yet. Share an insight, caveat, or question.
Amiri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: